The impact of global pharmaceutical mergers and acquisitions on the Nigerian pharmaceutical industry

Journal of Medical Marketing: Device, Diagnostic and Pharmaceutical Marketing

Volumn 5, Issue 4, 2005, Pages 370-382

  Erhun, Wilson O ^a   Demehin, Adeolu I ^b   Erhun, Mercy O ^b  

^a OBAFEMI AWOLOWO UNIVERSITY   (Nigeria)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84990365406     PISSN: 17457904     EISSN: 17457912     Source Type: Journal    
DOI: 10.1057/palgrave.jmm.5040256     Document Type: Article

References (26)

1. Arthur R. Waya H. (1963) ‘A critical study of accounting for business combinations’, Accounting Research Study, American Institute of Certified Accountants, New York, 7–8.
2. Breuer R.E. (1999) ‘Mega-mergers and business strategy’, Mergers, Business Strategy and the Global Economy. www.weforum.org/site/knowledgenavigator.nsf/content (Accessed February, 2005).
3. Hume C. (2000) ‘Confronting the giant’, Chemical Specialties, (A Chemical Week Associates publication), Sept-Oct. 4(5), 15–19.
4. Piachaud B.S. Moustakis F. (2000) ‘Is there a valid case for mergers within the defence and pharmaceutical industries? A qualitative analysis’, The Journal of World Affairs and New Technology, 3(4), 12–15.
5. PMG-MAN (2000) ‘The Pharmaceutical Industry in Nigeria: Historical Review, Problems and Expectations’ (unpublished).
6. Ayebae F. (2002) ‘Managing an industrial pharmaceutical business successfully in Nigeria’, Pharmanews, 24(9), 35–36.
7. Ayebae F. (2002) ‘Managing an industrial pharmaceutical business successfully in Nigeria’, Pharmanews, 24(9), 35–36.
8. Ebere E.O. (2003) ‘Taking PMG-MAN to its peak’, Corporate Elite, 2(5):20–23.
9. Nuhu S.Z. (2003) ‘The future of pharmacy in Nigeria: The challenges ahead’, Nigerian Journal of Pharmacy, 34, 11–14.
10. Erhun W.O. Babalola O.O. Erhun M.O. (2001) ‘Drug regulation and control in Nigeria: The challenge of counterfeit drugs’, Journal of Health and Population in Developing Countries, 4(2), 23–24.
11. Erhun W.O. Agunedu C.O. (1995) ‘Procurement and sale of drugs in a Nigerian market place’, Nigerian Journal of Pharmacy, 26(3/4), 30–34.
12. Akhimein A. (2005) ‘Effective drug distribution system in Nigeria: The role of government and the pharma-industry’, Pharmanews, 27(7), 36.
13. Jung J. (2003) ‘Your pharmaceutical merger: An opportunity to innovate or back to ‘business as usual’?, www.ibm.com/services/strategy (Accessed February, 2005).
14. Whittaker E. Bower J. (1994) ‘A shift to external alliances for drug development in the pharmaceutical industry’, R&D Management, 24, 249–260.
15. Hume (2000) R&D Management.
16. Gershon D. (2000) ‘Are mega-mergers good medicines for the pharmaceutical industry?’, Nature Medicine, 405(6782):257–259.
17. Jung J. (2003) ‘Creating breakthrough innovation during a pharmaceutical merger or acquisition’, www.ibm.com/services/strategy (Accessed January, 2005).
18. McKinnell H. (2003) ‘The first 100 days of a merger: Getting off to a fast start’, Perspectives, Issue 1, www.ketchumperspectives.com/archives/2003 (Accessed February, 2005).
19. Bogan C. Symmers K. (2001) ‘Marriages made in Heaven?’, Pharmaceutical Executive, 21(1), 52–58.
20. Mullin R. (2003) ‘The merging reality’, Chemical & Engineering Publication, CENEAR, 81(30), 23–32.
21. Afolabi M.O. Olayiwola G. Erhun W.O. (1999) ‘Partnership patterns of general practice pharmacy in Nigeria’, Nigerian Journal of Pharmacy, 30(3), 28–30.
22. Olori F. (2003) ‘Mergers and acquisitions for insurance companies’, Financial Standard, 5(7), 48–49.
23. Cookey P. (2003) ‘IBTC tips mergers and acquisitions as next economic phase’, Financial Standard, 5(7), 34–35.
24. Ayebae (2002) Financial Standard.
25. Hume (2000) Financial Standard.
26. Erhun, et al(2001) Financial Standard.